Surapol Issaragrisil

7.0k total citations · 2 hit papers
155 papers, 4.5k citations indexed

About

Surapol Issaragrisil is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Surapol Issaragrisil has authored 155 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Hematology, 52 papers in Molecular Biology and 43 papers in Genetics. Recurrent topics in Surapol Issaragrisil's work include Hematopoietic Stem Cell Transplantation (39 papers), Pluripotent Stem Cells Research (24 papers) and Hippo pathway signaling and YAP/TAZ (18 papers). Surapol Issaragrisil is often cited by papers focused on Hematopoietic Stem Cell Transplantation (39 papers), Pluripotent Stem Cells Research (24 papers) and Hippo pathway signaling and YAP/TAZ (18 papers). Surapol Issaragrisil collaborates with scholars based in Thailand, United States and Germany. Surapol Issaragrisil's co-authors include Sudjit Luanpitpong, Hagop M. Kantarjian, Richard A. Larson, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, Richard E. Clark, Gabriel Étienne, Paweorn Angsutararux and Ricardo Pasqüini and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Surapol Issaragrisil

150 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

2010 1.2k citations Giuseppe Saglio, Surapol Issaragrisil et al. profile →
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

2016 563 citations Andreas Hochhaus, Giuseppe Saglio et al. Leukemia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Surapol Issaragrisil Thailand	30	2.5k	1.9k	991	863	733	155	4.5k
Mhairi Copland United Kingdom	35	2.3k 0.9×	1.4k 0.7×	1.5k 1.6×	739 0.9×	681 0.9×	131	4.3k
Mark J. Koury United States	40	2.1k 0.8×	1.2k 0.6×	1.9k 1.9×	580 0.7×	532 0.7×	123	5.5k
Itaru Matsumura Japan	39	2.0k 0.8×	1.2k 0.6×	2.5k 2.6×	355 0.4×	1.4k 1.9×	216	5.5k
Sanford B. Krantz United States	42	3.3k 1.3×	2.1k 1.1×	1.5k 1.6×	574 0.7×	817 1.1×	123	5.8k
Sriram Krishnaswami United States	32	2.2k 0.9×	1.3k 0.7×	414 0.4×	3.9k 4.6×	1.4k 2.0×	59	6.1k
Arne Slungaard United States	35	1.8k 0.7×	571 0.3×	1.1k 1.1×	451 0.5×	1.5k 2.0×	68	5.1k
Daniela Cilloni Italy	33	2.7k 1.1×	1.6k 0.8×	1.6k 1.6×	676 0.8×	848 1.2×	181	4.4k
Taira Maekawa Japan	45	1.3k 0.5×	921 0.5×	1.9k 1.9×	525 0.6×	1.5k 2.0×	224	5.6k
Josef S Smolen Austria	19	1.6k 0.6×	824 0.4×	1.2k 1.2×	4.2k 4.8×	779 1.1×	26	6.5k
Yoshihisa Nojima Japan	40	972 0.4×	550 0.3×	2.2k 2.2×	509 0.6×	844 1.2×	231	6.1k

Countries citing papers authored by Surapol Issaragrisil

Since Specialization

Citations

This map shows the geographic impact of Surapol Issaragrisil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Surapol Issaragrisil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Surapol Issaragrisil more than expected).

Fields of papers citing papers by Surapol Issaragrisil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Surapol Issaragrisil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Surapol Issaragrisil. The network helps show where Surapol Issaragrisil may publish in the future.

Co-authorship network of co-authors of Surapol Issaragrisil

This figure shows the co-authorship network connecting the top 25 collaborators of Surapol Issaragrisil. A scholar is included among the top collaborators of Surapol Issaragrisil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Surapol Issaragrisil. Surapol Issaragrisil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laowtammathron, Chuti, et al.. (2025). Repurposing of an inotropic drug dobutamine to enhance the production of human hematopoietic stem cells from human induced pluripotent stem cells. Stem Cell Research & Therapy. 16(1). 298–298.

Luanpitpong, Sudjit, Xing Kang, Phatchanat Klaihmon, et al.. (2024). OGT and OGA gene-edited human induced pluripotent stem cells for dissecting the functional roles of O-GlcNAcylation in hematopoiesis. Frontiers in Cell and Developmental Biology. 12. 1361943–1361943. 1 indexed citations

Klaihmon, Phatchanat, et al.. (2024). Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib. Scientific Reports. 14(1). 3993–3993. 2 indexed citations

Laowtammathron, Chuti, Chanchao Lorthongpanich, Phatchanat Klaihmon, et al.. (2022). CRISPR/Cas9 mediated approach to generate YAP-depleted human embryonic stem cell line (MUSIe002-A-1). Stem Cell Research. 66. 102990–102990. 1 indexed citations

Luanpitpong, Sudjit, Xing Kang, Kanjana Thumanu, et al.. (2022). Metabolic sensor O-GlcNAcylation regulates erythroid differentiation and globin production via BCL11A. Stem Cell Research & Therapy. 13(1). 274–274. 6 indexed citations

Lorthongpanich, Chanchao, et al.. (2020). Effect of YAP/TAZ on megakaryocyte differentiation and platelet production. Bioscience Reports. 40(8). 8 indexed citations

Laowtammathron, Chuti, et al.. (2020). Derivation of human embryonic stem cell line MUSIe001-A from an embryo with homozygous α0-thalassemia (SEA deletion). Stem Cell Research. 43. 101695–101695. 2 indexed citations

Wattanapanitch, Methichit, et al.. (2018). An integration-free iPSC line (MUSIi008-A) derived from a patient with severe hemolytic anemia carrying compound heterozygote mutations in KLF1 gene for disease modeling. Stem Cell Research. 34. 101344–101344. 1 indexed citations

Bacigalupo, Andrea, Rosi Oneto, Hubert Schrezenmeier, et al.. (2018). First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001‐2012. American Journal of Hematology. 93(5). 643–648. 34 indexed citations

10.

U‐pratya, Yaowalak, et al.. (2017). Dengue Virus and Its Relation to Human Glycoprotein IIb/IIIa Revealed by Fluorescence Microscopy and Flow Cytometry. Viral Immunology. 30(9). 654–661. 3 indexed citations

11.

Wanachiwanawin, Wanchai, et al.. (2017). The Incidence of Aplastic Anemia in Thailand: Experiences from a Nationwide Registry. Blood. 130. 4965–4965. 1 indexed citations

12.

Luanpitpong, Sudjit, et al.. (2017). Hyper-O-GlcNAcylation induces cisplatin resistance via regulation of p53 and c-Myc in human lung carcinoma. Scientific Reports. 7(1). 10607–10607. 40 indexed citations

13.

Hochhaus, Andreas, Giuseppe Saglio, Timothy P. Hughes, et al.. (2016). Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 30(5). 1044–1054. 563 indexed citations breakdown →

14.

Tirawanchai, Nednapis, et al.. (2012). Epigenetic Analysis and Suitability of Amniotic Fluid Stem Cells for Research and Therapeutic Purposes. Stem Cells and Development. 22(9). 1319–1328. 10 indexed citations

15.

Auewarakul, Prasert, et al.. (2000). TT virus infection in Thailand: prevalence in blood donors and patients with aplastic anemia.. PubMed. 72(3). 325–8. 7 indexed citations

16.

Issaragrisil, Surapol. (1999). Epidemiology of aplastic anemia in Thailand. Thai Aplastic Anemia Study Group.. PubMed. 70(3). 137–40. 10 indexed citations

17.

Issaragrisil, Surapol, Paul E. Leaverton, Kanchana Chansung, et al.. (1999). Regional patterns in the incidence of aplastic anemia in Thailand. American Journal of Hematology. 61(3). 164–168. 3 indexed citations

18.

Issaragrisil, Surapol, David W. Kaufman, Kanchana Chansung, et al.. (1997). Association of seropositivity for hepatitis viruses and aplastic anemia in Thailand. Hepatology. 25(5). 1255–1257. 15 indexed citations

19.

Issaragrisil, Surapol, David W. Kaufman, Theresa Anderson, et al.. (1997). Low drug attributability of aplastic anemia in Thailand. The Aplastic Anemia Study Group.. Blood. 89(11). 4034–9. 39 indexed citations

20.

Issaragrisil, Surapol, et al.. (1988). Studies on the pathogenesis of aplastic anemia in Thailand: evidence of immune-mediated mechanism.. PubMed. 6(1). 33–7. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact